Q&A: BeiGene ex­ec re­flects on path that led them to se­lect NJ for a ma­jor man­u­fac­tur­ing/R&D cam­pus

4 years ago
Manufacturing

A Texas-based phar­ma has en­list­ed Catal­ent for oral sol­id man­u­fac­tur­ing; Cy­ti­va drops mas­sive man­u­fac­tur­ing ...

4 years ago
Manufacturing

Celu­lar­i­ty teams up with Aus­tralian biotech to de­vel­op CAR T-cell ther­a­py; For­mer Kin­nate CEO Stephen Kaldor reels in ...

4 years ago
News Briefing

Ox­ford spin­out rais­es $113M in bid to beat Sarep­ta's Ex­ondys 51 in DMD. But will we ever know if any of the drugs ...

4 years ago
Financing

Lib­tayo, chemo com­bo clears lung can­cer tri­al two years ear­ly. But can it com­pete with Keytru­da?

4 years ago
R&D

Gilead’s Kite jumps back to the bar­gain­ing ta­ble to forge $875M pact with a new­ly-emerged up­start on next-gen cell ...

4 years ago
Deals

Mod­er­na's Covid-19 vac­cine sales to trail Pfiz­er's to­tal sig­nif­i­cant­ly in 2021 and 2022

4 years ago
R&D
Coronavirus

Mer­ck­'s Keytru­da takes home ad­ju­vant win in melanoma, es­ca­lat­ing ear­ly-line fight with Bris­tol My­ers

4 years ago
R&D
Pharma

ICER of­fers fi­nal ver­dict against Bio­gen's ad­u­canum­ab: No proof it works, clear prospect of harm, wild­ly over­priced

4 years ago
FDA+

Covid-19 roundup: Pfiz­er im­pos­es vac­cine man­date for US work­ers; WHO calls for mora­to­ri­um on boost­ers, while some ...

4 years ago
Coronavirus

Emerg­ing from stealth mode, Aard­vark rounds up enough cash to put its lead drug through Prad­er-Willi PhII

4 years ago
Financing

UK re-in­ves­ti­gates Pfiz­er's eye-pop­ping price goug­ing on an epilep­sy drug

4 years ago
Pharma

A small vac­cine de­vel­op­er fa­vored by the UK gov­ern­ment in Covid-19 touts a PhI­II first in chikun­gun­ya

4 years ago
R&D

Bay­er nabs star biotech Vi­vid­ion with a $2B buy­out and an ‘arms-length’ pact, pulling a part­ner out of the IPO ...

4 years ago
Deals

Sci­ence pi­o­neer, phar­ma re­search chief, glob­al health ad­vo­cate and biotech en­tre­pre­neur Tadata­ka ‘Tachi’ Ya­ma­da ...

4 years ago
People

Zymer­gen's sud­den im­plo­sion shocked biotech. A lin­ger­ing loan could make things even worse

4 years ago
Financing

HHS ex­tends Aduhelm in­ves­ti­ga­tion in­to the ac­cel­er­at­ed ap­proval path­way, wad­ing in­to a brew­ing con­tro­ver­sy

4 years ago
FDA+

Shares of Be­yond­Spring sky­rock­et on new, pos­i­tive can­cer drug tri­al re­sults

4 years ago
R&D

Pfiz­er puts the pres­sure on Eli Lil­ly's JAK in­hibitor Olu­mi­ant with new da­ta in alope­cia area­ta

4 years ago
R&D

Am­gen adds new NC plant to the list as part of $1B man­u­fac­tur­ing ex­pan­sion plans state­side

4 years ago
Manufacturing

Am­gen may see $3B+ in ad­di­tion­al tax­es; EQRx, Ab­Cellera ink an­ti­body de­vel­op­ment deal

4 years ago
News Briefing

Bio­gen, Ei­sai are push­ing for an­oth­er ac­cel­er­at­ed Alzheimer's OK — this time for BAN2401

4 years ago
FDA+

Soft­Bank claims $5B stake in Roche amid grand plans to in­vest in biotech — re­ports

4 years ago
Deals

Saman­tha Du's Zai Lab inks sur­pris­ing re­search col­lab with Schrödinger for DNA dam­age drug

4 years ago
Deals
R&D
First page Previous page 655656657658659660661 Next page Last page
A service from the Financial Times